A Phase 2 interventional study of NS-018 and Best Available Therapy in Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis and Post-polycythemia Vera Myelofibrosis, sponsored by NS Pharma, Inc.. Terminated at 52 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by NS Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Primary Myelofibrosis with a site in Italy — 24 open to participants now, 43 under way, 11 of them phase 3. Primary Myelofibrosis · Italy.
Among the 101 studies in Primary Myelofibrosis with a site in Italy, this one is the 81st largest by enrollment of the 83 interventional ones that give a count, is one of 5 that started in 2023, is one of 27 in phase 2, and was the 71st registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →24 of the 101 studies in Primary Myelofibrosis with a site in Italy are open now. Recruiting first, the newest first:
Takeda · Sites in Italy, United States, Argentina and 28 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 21 more countries
Ages 18+
Incyte Corporation · Sites in Italy, United States, Australia and 8 more countries
Ages 18+
Prelude Therapeutics Incorporated · Sites in Italy, United States, Australia and 2 more countries
Ages 18+
iOnctura · Sites in Italy, Spain, United Kingdom
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 40 · Phase 3 25 · Phase 4 1
First in 1999; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 121 across the 83 interventional studies, 448 across the 18 observational. Of the 55 that completed or were terminated, 33 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 101 have an industry lead sponsor. The 10 most frequent:
NS Pharma, Inc. is the lead sponsor of 16 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
NS Pharma, Inc. has 2 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
12 of the studies in Primary Myelofibrosis with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479135Phase 3Kartos Therapeutics, Inc.Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | 2026-12-31 |
| NCT01761968ItalfarmacoLong-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | 2026-12 |
| NCT03441113GlaxoSmithKlineExtended Access of Momelotinib in Adults With Myelofibrosis | 2026-12-11 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT04454658AbbVieSafety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 101 studies in Primary Myelofibrosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will enroll male and female subjects who are 18 years of age or older with Primary Myelofibrosis, post-polycythemia Vera Myelofibrosis, or post-essential Thrombocythemia Myelofibrosis with severe thrombocytopenia (platelet count \<50,000/µL) including subjects with intermediate-2 or high-risk MF according to the Dynamic International Prognostic Scoring System (DIPSS).
NS-018 will be self-administered orally at a dose of 300 mg BID. The BAT will be administered according to manufacturer's instructions and Investigator discretion. Subjects will complete study visits at Screening, Day 1 and Day 15 of Cycle 1, 2, 3, 4, 5, 6 and Day 1 of every cycle thereafter. At these visits, blood/urine sampling, spleen measurements, bone marrow assessments, patient-reported outcome (PRO) assessments, and safety assessments may be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Self-administered NS-018 300 mg orally, twice daily, preferably at the same time each day in consecutive 4-week (28-day) cycles
Drug: NS-018
Single agent per Investigator discretion or no therapy
Drug: Best Available Therapy
Experimental
Active Comparator
Change in Spleen Volume
Proportion of subjects who achieve ≥35% reduction in spleen volume from baseline compared to Week 24 as measured by MRI (or by CT for applicable subjects)
Time frame: baseline and week 24
Change in Total Symptom Score (TSS)
Proportion of subjects who achieve ≥50% reduction in total symptom score from baseline compared to Week 24 as measured by the MF-SAF v4.0
Time frame: baseline and week 24
Change in Spleen Volume
Proportion of subjects in NS-018 vs BAT arm who achieve ≥35% reduction in spleen volume from baseline at any time up to Week 24 as measured by MRI (or by CT for applicable subjects)
Time frame: from baseline to anytime before or at week 24
Comparison of Treatment-emergent AEs Between NS-018 and BAT
Laboratory events graded by the NCI CTCAE v5.0 will be assessed in both arms, to compare the safety profile of NS-018 versus BAT.
Time frame: from baseline to week 24
| Milestone | NS-018 | Best Available Therapy (BAT) |
|---|---|---|
| Started | 5 | 2 |
| Completed | 0 | 0 |
| Not completed | 5 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Study terminated by sponsor due to business reasons. | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Other reasons | 1 | 0 |
Proportion of subjects who achieve ≥35% reduction in spleen volume from baseline compared to Week 24 as measured by MRI (or by CT for applicable subjects)
| Participants | NS-018 | Best Available Therapy (BAT) |
|---|---|---|
| Change in Spleen Volume | 0 | 0 |
Proportion of subjects who achieve ≥50% reduction in total symptom score from baseline compared to Week 24 as measured by the MF-SAF v4.0
| Participants | NS-018 | Best Available Therapy (BAT) |
|---|---|---|
| Change in Total Symptom Score (TSS) | 0 | 1 |
Proportion of subjects in NS-018 vs BAT arm who achieve ≥35% reduction in spleen volume from baseline at any time up to Week 24 as measured by MRI (or by CT for applicable subjects)
| Participants | NS-018 | Best Available Therapy (BAT) |
|---|---|---|
| Change in Spleen Volume | 1 | 0 |
Laboratory events graded by the NCI CTCAE v5.0 will be assessed in both arms, to compare the safety profile of NS-018 versus BAT.
| Participants | NS-018 | Best Available Therapy (BAT) |
|---|---|---|
| Comparison of Treatment-emergent AEs Between NS-018 and BAT | 5 | 2 |
Collected over from baseline to week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NS-018 | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Best Available Therapy (BAT) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | NS-018 | Best Available Therapy (BAT) |
|---|---|---|
| TracheobronchitisInfections and infestations | 1/5 | 0/2 |
| Event | NS-018 | Best Available Therapy (BAT) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 4/5 | 0/2 |
| Conjunctival haemorrhageEye disorders | 1/5 | 1/2 |
| Eyelid function disorderEye disorders | 0/5 | 1/2 |
| Abdominal PainGastrointestinal disorders | 1/5 | 1/2 |
| Lower respiratory tract infectionInfections and infestations | 0/5 | 1/2 |
| HypokalaemiaMetabolism and nutrition disorders | 2/5 | 1/2 |
| Neuropathy peripheralNervous system disorders | 0/5 | 1/2 |
| Affective disorderPsychiatric disorders | 0/5 | 1/2 |
| InsomniaPsychiatric disorders | 0/5 | 1/2 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/5 | 1/2 |
| Age, Categorical(Participants) | NS-018 | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 0 | 2 |
| >=65 years | 3 | 2 | 5 |
| Age, Continuous(Years) | NS-018 | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| Mean | 65.0 ± 16.48 | 70.5 ± 0.71 | 66.6 ± 13.72 |
| Sex: Female, Male(Participants) | NS-018 | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| Female | 3 | 1 | 4 |
| Male | 2 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | NS-018 | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 2 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | NS-018 | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 2 | 2 | 4 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Submission to the FDA
Ran from Jan 2023 to primary completion in May 2024, 15 months.
Results were first posted in May 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NS Pharma, Inc.